The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist

American Journal of Therapeutics

Volumn 22, Issue 3, 2015, Pages 171-181

  Preston, Richard A ^a,b,c   Marbury, Thomas C ^d   Wajima, Toshihiro ^e   Graham, Shelli ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

^e SHIONOGI AND CO LTD   (Japan)

Author keywords

hepatic impairment; ospemifene; postmenopausal women; renal impairment

Indexed keywords

ALLOPURINOL; AMLODIPINE; CALCITRIOL; FUROSEMIDE; METOPROLOL; OMEPRAZOLE; OSPEMIFENE; PARACETAMOL; ROSUVASTATIN; SALBUTAMOL; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ALLERGY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMATOMA; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; KIDNEY FAILURE; LIVER FAILURE; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; MYALGIA; NAUSEA; OPEN STUDY; OROPHARYNX PAIN; PELVIC PAIN; PLASMA CONCENTRATION-TIME CURVE; POSTMENOPAUSE; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINAL DRYNESS; VOMITING; VULVOVAGINAL DISCOMFORT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; METABOLISM;

ADULT; AGED; AREA UNDER CURVE; ESTROGENS; FEMALE; HEPATIC INSUFFICIENCY; HUMANS; MIDDLE AGED; RENAL INSUFFICIENCY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84929514910     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/01.mjt.0000434044.39502.64     Document Type: Article

References (11)

1. Gennari L. Ospemifene Hormos. Curr Opin Investig Drugs. 2004;5:448-455.
2. Voipio SK, Komi J, Kangas L, et al. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. 2002;43:207-214.
3. Komi J, Lankinen KS, Härkönen P, et al. Effects of ospe-mifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005;12:202-209.
4. Rutanen EM, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmeno-pausal women: a double-blind, randomized trial. Menopause. 2003;10:433-439.
5. Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20:418-427.
6. Portman DJ, Bachmann GA, Simon JA, et al. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20:623-630.
7. Committee for Medicinal Products for Human Use. Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients With Impaired Hepatic Function. London, UK: European Medicines Agency; 2005.
8. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville, MD: Center for Drug Evaluation and Research; 2003.
9. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transec-tion of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
11. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Pharmacokinetics in Patients With Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville, MD: Center for Drug Evaluation and Research; 2010.